Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cree B. A. C., Bennett J. L., Kim H. J., Weinshenker B. G., Pittock S. J., Wingerchuk D. M., ...More

LANCET, vol.394, no.10206, pp.1352-1363, 2019 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 394 Issue: 10206
  • Publication Date: 2019
  • Doi Number: 10.1016/s0140-6736(19)31817-3
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1352-1363
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

Background No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.